Answers are grounded in this paper and cite their sources.
Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: